ATRA

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, Juni 7, 2024
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, Employment, ATRA, Epstein–Barr virus, EBV, Patient, Compensated emancipation, Cancer

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.
  • This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of June 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Retrieved on: 
Mittwoch, Juni 5, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, PDT, Webcast, Patient, ATRA, EDT, Epstein–Barr virus, EBV, Conference, Cancer

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 6:20 a.m. PDT / 9:20 a.m. EDT.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 6:20 a.m. PDT / 9:20 a.m. EDT.
  • A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Retrieved on: 
Mittwoch, Mai 29, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, EBV, Patient, Cell, Epstein–Barr virus, Phenotype, ISCT, Toxicity, SLE, Cytokine, CD19, International Society, ATRA, Cancer, Autoimmunity, PDT, IL-6, NHL, Inflammation, Lupus nephritis, Annual general meeting, Vaccine

Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.

Key Points: 
  • Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.
  • The data will be presented in a poster session at the International Society for Cell & Gene Therapy (ISCT) 2024 Annual Meeting taking place May 29 to June 1, 2024, in Vancouver, Canada.
  • ATA3219 consists of allogeneic CD19-directed CAR EBV T cells that have been optimized to offer a potential best-in-class profile and off-the-shelf availability.
  • “We are pleased to share promising preclinical data that shows ATA3219 mediates robust B-cell depletion against SLE and multiple sclerosis patient derived immune cells.

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Retrieved on: 
Montag, Mai 20, 2024
Surgery, FDA, Genetics, Clinical Trials, Stem Cells, Practice Management, Biotechnology, Health, Pharmaceutical, EBV, Patient, Epstein–Barr virus, Food, Lymphoproliferative disorders, PTLD, ATRA, Cancer, Biologics license application, BLA, Physician, Pharmaceutical industry

There are no FDA approved therapies in this treatment setting.

Key Points: 
  • There are no FDA approved therapies in this treatment setting.
  • Tab-cel has been granted Breakthrough Therapy Designation for the treatment of rituximab-refractory EBV-associated lymphoproliferative disease by the U.S. FDA and has orphan drug designation.
  • In addition, Pierre Fabre is reimbursing Atara for expected tab-cel global development costs through the BLA transfer and purchasing tab-cel inventory through the manufacturing transfer date.
  • Atara is also eligible to receive double-digit tiered royalties on net sales of tab-cel in the U.S. and remaining global commercial markets referenced above.

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
Donnerstag, Mai 9, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Mantle cell lymphoma, Cancer, International Society, Investment, Cell, Phenotype, Safety, Risk, Pharmacokinetics, Poster, Lymphoproliferative disorders, Depreciation, Cytokine, Partnership, Lymphoma, Biologics license application, ATRA, Follicular lymphoma, CD19, ASH, Epstein–Barr virus, Patient, NHL, LD, Toxicity, BLA, Memory, Workforce, EBV, Biomarker, SLE, Tabelecleucel, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  • “This is anticipated to provide multiple near-term clinical milestones for ATA3219, including initial non-Hodgkin’s lymphoma data expected in the fourth quarter 2024, and initial lupus nephritis data in the first half of 2025, with plans to expand into a new SLE cohort without lymphodepletion.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, Mai 3, 2024
Biotechnology, Pharmaceutical, Health, Oncology, EBV, Cancer, Epstein–Barr virus, Compensated emancipation, Patient, Employment, ATRA

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.
  • This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of May 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Madison Pacific Properties Inc. announces the results for the six months ended February 29, 2024

Retrieved on: 
Samstag, April 13, 2024
MPC, CRA, International, Tax court, Comprehensive, TSX, ATRA, Tax, International Financial Reporting Standards, Canada Revenue Agency, MPP, TCC, Federal court, Life insurance

VANCOUVER, British Columbia, April 12, 2024 (GLOBE NEWSWIRE) -- Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the six months ended February 29, 2024.

Key Points: 
  • VANCOUVER, British Columbia, April 12, 2024 (GLOBE NEWSWIRE) -- Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the six months ended February 29, 2024.
  • Also included in net loss is a net gain on the fair value adjustment on investment properties of approximately $4.3 million (2023: $14.0 million).
  • The decision denied Madison Pacific Properties Inc.’s ability to use certain carryforward losses for certain taxation years within its 2009 to 2017 taxation years.
  • As at February 29, 2024, the Company owns approximately $709 million in investment properties, including the Company’s proportionate share of investment properties held through joint operations.

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

Retrieved on: 
Mittwoch, April 24, 2024
Biotechnology, Health, General Health, Public Relations, Investor Relations, Pharmaceutical, Oncology, Communications, Other Science, Research, Science, Clinical Trials, Cancer, Prostate, HER2, Doxorubicin, Abstract, Stomach, Breast, Tumor microenvironment, Uterus, ATRA, ASCO, Therapy, Patient, Society, Lung

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.

Key Points: 
  • HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.
  • “The ASCO meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators,” said Yuhong Xu, Ph.D., Founder and CEO of HighField.
  • HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression.
  • HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, EBV, Epstein–Barr virus, ATRA, Patient, Employment, Cancer, Compensated emancipation

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
  • This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
Donnerstag, März 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.